SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-21-210842
Filing Date
2021-07-08
Accepted
2021-07-08 16:31:52
Documents
3
Group Members
VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D d192175dsc13d.htm SC 13D 129492
2 EX-99.1 d192175dex991.htm EX-99.1 7645
3 EX-99.3 d192175dex993.htm EX-99.3 29751
  Complete submission text file 0001193125-21-210842.txt   168635
Mailing Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Subject) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92649 | Film No.: 211080516
SIC: 2836 Biological Products, (No Diagnostic Substances)